Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | WDR5 | P61964 | 3/20 | 0.44 |
| ▸ | BRS3 | P32247 | 2/20 | 0.43 |
| ▸ | ATP4A | P20648 | 5/20 | 0.42 |
| ▸ | ATP4B | P51164 | 5/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.42 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.42 |
| ▸ | ATP1A1 | P05023 | 2/20 | 0.42 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.42 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.42 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.42 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.42 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.42 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.42 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2615442 | 1.00 | KMT2A (0.44) | KMT2AWDR5BRS3ATP4AATP4B | |
| SCHEMBL15032050 | 1.00 | KMT2A (0.44) | KMT2AWDR5BRS3ATP4AATP4B | |
| Esomeprazole SCHEMBL144577 | 0.92 | BRS3 (0.51) | KMT2AWDR5BRS3ATP4AATP4B | |
| Omeprazole SCHEMBL589807 | 0.92 | BRS3 (0.51) | KMT2AWDR5BRS3ATP4AATP4B | |
| Esomeprazole SCHEMBL28300201 | 0.92 | BRS3 (0.51) | KMT2AWDR5BRS3ATP4AATP4B | |
| Omeprazole SCHEMBL665194 | 0.92 | BRS3 (0.51) | KMT2AWDR5BRS3ATP4AATP4B | |
| SCHEMBL12878864 | 0.92 | BRS3 (0.50) | KMT2AWDR5BRS3ATP4AATP4B | |
| SCHEMBL10617038 | 0.92 | BRS3 (0.50) | KMT2AWDR5BRS3ATP4AATP4B | |
| Esomeprazole SCHEMBL142905 | 0.91 | BRS3 (0.50) | KMT2AWDR5BRS3ATP4AATP4B | |
| Omeprazole SCHEMBL1713666 | 0.91 | BRS3 (0.50) | KMT2AWDR5BRS3ATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150238463-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR | SHAHID MUSLIM D (US) | 2015-08-27 | — | — | US | claimed |
| EP-0045200-B1 | BENZIMIDAZOLES AND THEIR PHARMACEUTICAL USE | THE UPJOHN COMPANY (US) | 1988-03-02 | — | — | EP | claimed |
| EP-0005129-B1 | SUBSTITUTED PYRIDYLSULFINYLBENZIMIDAZOLES HAVING GASTRIC ACID SECRETION PROPERTIES, PHARMACEUTICAL PREPARATIONS CONTAINING SAME, AND INTERMEDIATES FOR THEIR PREPARATION | Aktiebolaget Hässle (SE) | 1981-04-29 | — | — | EP | claimed |
| US-9522924-B1 | Pyridone derivatives as acid secretion inhibitors and process for preparation thereof | EMCURE PHARMACEUTICALS LIMITED (IN) | 2016-12-20 | — | — | US | disclosed |
| US-20160355529-A1 | PYRIDONE DERIVATIVES AS ACID SECRETION INHIBITORS AND PROCESS FOR PREPARATION THEREOF | EMCURE PHARMACEUTICALS LTD (IN) | 2016-12-08 | — | — | US | disclosed |
| US-9447094-B2 | Pyridone derivatives as acid secretion inhibitors and process for preparation thereof | EMCURE PHARMACEUTICALS LIMITED (IN) | 2016-09-20 | — | — | US | disclosed |
| US-20150232467-A1 | PYRIDONE DERIVATIVES AS ACID SECRETION INHIBITORS AND PROCESS FOR PREPARATION THEREOF | EMCURE PHARMACEUTICALS LTD (IN) | 2015-08-20 | — | — | US | disclosed |
| US-8173158-B2 | Methods of treating gastrointestinal disorders independent of the intake of food | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2012-05-08 | — | — | US | disclosed |
| EP-0045200-B1 | BENZIMIDAZOLES AND THEIR PHARMACEUTICAL USE | THE UPJOHN COMPANY (US) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232467-A1 | PYRIDONE DERIVATIVES AS ACID SECRETION INHIBITORS AND PROCESS FOR PREPARATION THEREOF | PDXK, PLPBP, HRH2 | KMT2A 3671/4885WDR5 3690/4885BRS3 113/4885 |
| US-20150238463-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR | FABP6, ALAD, SLC10A2 | KMT2A 4550/4885WDR5 3753/4885BRS3 1929/4885 |
| US-20160355529-A1 | PYRIDONE DERIVATIVES AS ACID SECRETION INHIBITORS AND PROCESS FOR PREPARATION THEREOF | PDXK, PLPBP, HRH2 | KMT2A 3671/4885WDR5 3690/4885BRS3 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.